

KCR'S 2014 YEAR OF SUCCESS

KCR COMPLETED IN 2014 ONE OF ITS BEST YEARS IN THE COMPANY HISTORY WITH A STRONG BUSINESS PERFORMANCE AND EXTENDED GEOGRAPHICAL COVERAGE

5 YEARS = PREFERRED FSP

PREFERRED FSP FOR ONE OF THE WORLD'S LARGEST BIOTECH COMPANIES FOR NEXT 5 YEARS

BOOK-TO-BILL RATIO INCREASED

REPORTED 1.5
EXPECTED 1.2

RAISED REVENUE BY

415%
IN MEDICAL MONITORING AND CLINICAL DEVELOPMENT CONSULTING SERVICES

4 NEW

SUBSIDIARIES LAUNCHED IN WESTERN EUROPE

BERLIN

SELECTED AS A NEW HEAD OFFICE LOCATION IN EUROPE

STRENGTHENED POSITION IN UKRAINE BY ACQUIRING AXIS PROJECT PORTFOLIO

INCREASED BY

30%



THE NUMBER OF STUDIES CONDUCTED IN THE NICHE AREA OF PEDIATRIC PAIN MANAGEMENT



SELECTED AS A CLINICAL SERVICES PROVIDER BY 2 TOP AMERICAN BIOTECH COMPANIES FOR CONDUCTING THEIR 1ST NON-US MULTINATIONAL PHASE II AND PHASE II STUDIES

LATE PHASE TRIALS EXECUTION

ESTABLISHED AS A SEPARATE BUSINESS LINE WITH SPECIALIZED PROCESSES AND TECHNOLOGY FOR COST-EFFICIENT GLOBAL USE



MIKE JAGIELSKI, CEO OF KCR:

“ After finalizing one of the best years in the KCR history, we look forward to further enhancing our existing offer and adding new service categories that evolve in the CRO industry. With the decision of moving our Head Office to Berlin we will stay closer to KCR existing and new clients to continue our trusting relationships. As we have enjoyed successful business operations in Europe last year, we now target the U.S. as our extending operations territory. ”

KCR